XOMA (LTS:0M26) NonCurrent Deferred Liabilities : $6.69 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is XOMA NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

XOMA's non-current deferred liabilities for the quarter that ended in Mar. 2024 was $6.69 Mil.

XOMA NonCurrent Deferred Liabilities Historical Data

The historical data trend for XOMA's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA NonCurrent Deferred Liabilities Chart

XOMA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

15.32

13.52

11.69

9.55

7.23

XOMA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															9.04	8.45	7.80	7.23	6.69

XOMA NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of XOMA's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA (LTS:0M26) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (LTS:0M26) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA X0M1:Germany

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA (LTS:0M26) Headlines

No Headlines